With an MHRA-approved GMP (Good Manufacturing Practice) compliant Clinical Manufacturing Facility outside Glasgow, TC Biopharm is commercialising unique biological properties exhibited by gamma delta T cells .
TC BioPharm has developed ImmuniCell®, an autologous therapy which involves cleanroom-based expansion of the cells over a 2 week period to formulate a treatment for a wide-variety of different tumour types and viral infections. The manufacturing process comprises several steps – isolation of peripheral blood mononuclear cells, selection/activation of gamma delta T cells and culture expansion in a GMP environment, providing therapeutically relevant cell numbers prior to administration.
Present as a small sub-population of circulating lymphocytes, gamma delta T cells recognise and target specific structures present on the surface of cancerous cells, and cells that have been virally infected. On recognising these cell-surface components, gamma delta T cells kill their target by injecting a potent toxin (granzyme) which induces cell death (apoptosis).